Human care company Elekta AB (STO:EKTAB.ST) announced on Thursday that MedTech Breakthrough, an independent organisation that recognises the top companies and solutions in the global health and medical technology market, has presented the 'Medical Device Engineering Breakthrough' award in the 2019 MedTech Breakthrough Awards programme to Elekta for its Elekta Unity MR-linac.
According to the company, Elekta Unity combines two technologies. One is a state-of-the-art 1.5T MRI scanner and the second a best-in-class 7 MV linear accelerator, driven by breakthrough real-time adaptive radiotherapy software. It provides the ability to reshape the dose based on daily changes in shape, size and position of the tumour and surrounding healthy anatomy, as visualised with MRI, and then enables accurate dose delivery with real-time visualization of the tumour.
Also, through Elekta Unity's integrated and responsive software, tumours and surrounding tissue can be precisely located, their movement tracked and treatment adapted in real time based on live information. This allows treatment plans to be adapted while the patient is on the table in response to changes in tumour position, shape, biology and the relationship to sensitive organs over time.
Reportedly, the mission of the MedTech Breakthrough Awards is to honour excellence and recognise the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records, mHealth, Medical Devices, Medical Data and many more. This year's programme attracted more than 3,500 nominations from over 15 different countries throughout the world.
Elekta offers precise, personalised radiotherapy treatments.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project